- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04341545
Letrozole in Tubal Ectopic Pregnancy
Randomized Controlled Trial on Use of Letrozole in the Medical Management of Tubal Ectopic Pregnancies
This is a multi-centred randomized controlled trial on the addition of letrozole in the medical management of tubal ectopic pregnancies.
Tubal ectopic pregnancies are abnormal pregnancies in the Fallopian tube, rather than in the womb. They occurred in around 1-2% of all pregnancies. Methotrexate (MTX) given by the intramuscular route i.e. systemic, a commonly used drug for cancer , was a widely used alternative for management for unruptured tubal ectopic pregnancies and was recommended as first line treatment for selected women.
Letrozole, aromatase inhibitor, can suppose oestradiol level. Combination of letrozole with misprostol has shown to improve the complete abortion rate in miscarriage. As a result, addition of letrozole may cause a higher success rate in the medical treatment of ectopic pregnancy.
As the evidence of combination of MTX and letrozole in tubal ectopic pregnancies is not available, the objective of the present study is to evaluate the efficacy of combination of MTX and letrozole compared to MTX alone in women with tubal ectopic pregnancies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Tubal ectopic pregnancies occur in around 1-2% of all pregnancies. Traditionally, surgery with salpingectomy was the mainstay of treatment; however, it comes with anaesthetic and operatives risks in addition to an increased cost for operative procedures. In recent years, systemic methotrexate (MTX), a dihydrofolate reductase inhibitor, has been a widely used alternative for management for unruptured tubal ectopic pregnancies. The success rate of systemic MTX at a doses of 50mg/m2 body surface area is around 70% which ranges from 65 to 95%, depending greatly on the level of human chorionic gonadotrophin (hCG), the size of adnexal mass and presence of fetal heart pulsation.
Use of systemic MTX as the first-line management has been proposed for women with unruptured ectopic pregnancy where the adnexal mass is smaller than 35mm, serum hCG level is less than 5000 IU/l and fetal heartbeat is absent.
Letrozole is a third generation non-steroidal reversible aromatase inhibitor. It can suppress oestradiol level up to 95% to 99% after administration according to pharmacodynamics and pharmacokinetics studies. Oestrogen is important in the support of early pregnancy, other than progesterone with well-known pivotal effect on the maintenance of early pregnancy.
Animal studies showed the combination of mifepristone and letrozole worked synergistically and induced almost 100% termination of pregnancies in rats. Letrozole induced 50% miscarriage rate in pregnant baboons. Letrozole combined with vaginal misoprostol regimen was associated with a higher complete abortion rate than misoprostol alone in pregnancies up to 63 days.
The use of letrozole in ectopic pregnancy has never been explored. It is hypothesized that letrozole can suppress serum oestradiol level, which in turn, may cause failure of pregnancy in ectopic pregnancy. The aim of this study is to investigate the clinical effectiveness of letrozole in addition to MTX in the medical treatment of ectopic pregnancy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Evelyn Wong, MBBS
- Phone Number: 22554517
- Email: evelynwong.ew@gmail.com
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Department of Obstetrics and Gynaecology, Queen Mary Hospital
-
Contact:
- Karen Chan, Prof
- Phone Number: 22554647
- Email: kklchan@hku.hk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Presence of heterogenous adnexal mass on USG suggestive of tubal ectopic pregnancy with hCG level >=1500 IU/L and <= 5000 IU/L
- Absence of fetal heart pulsation
- Mean diameter of adnexal mass <= 3.5cm
- Haemodynamically stable
- No significant abdominal pain
Exclusion Criteria:
- Presence of significant amount of free fluid in pelvis
- Allergic to MTX
- Deranged liver function test (AST/ ALT or GGT >= 2 upper limit of normal)
- Deranged renal function test (eGFR <= 45ml/min)
- Heterotopic pregnancies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Letrozole
Participants will be given letrozole 10mg daily for one week after standard medical management for tubal ectopic pregnancy by methotrexate injection.
Subsequently they will receive the standard management for medical management of tubal ectopic prengnacies.
|
Letrozole 10mg daily for one week.
Other Names:
|
Placebo Comparator: Placebo
Participants will be given identical looking placebo for one week and receive the same standard management for medical management of tubal ectopic pregnancies.
|
Placebo 4 tablets a day for one week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment success
Time Frame: 2 months
|
Proportion of women with treatment success defined as normalization of serum hCG level <10IU/L without additional medical or surgical intervention
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hCG normalization duration
Time Frame: 2 months
|
Duration of time until hCG normalization measured in days
|
2 months
|
Number of participants experienced side effects
Time Frame: 2 months
|
Side effects after letrozole
|
2 months
|
Duration of hospitalization
Time Frame: 2 months
|
Duration of hospitalization
|
2 months
|
Participant satisfaction: proportion of women who would recommend this treatment to a friend
Time Frame: 2 months
|
Treatment satisfaction measured as proportion of women who would recommend this treatment to a friend
|
2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Ernest H.Y. Ng, MD, The University of Hong Kong
Publications and helpful links
General Publications
- Shi L, Shi SQ, Given RL, von Hertzen H, Garfield RE. Synergistic effects of antiprogestins and iNOS or aromatase inhibitors on establishment and maintenance of pregnancy. Steroids. 2003 Nov;68(10-13):1077-84. doi: 10.1016/j.steroids.2003.09.002.
- Lee VCY, Ng EHY, Yeung WSB, Ho PC. Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial. Obstet Gynecol. 2011 Feb;117(2 Pt 1):317-323. doi: 10.1097/AOG.0b013e3182073fbf.
- Lee VC, Tang OS, Ng EH, Yeung WS, Ho PC. A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days. Contraception. 2011 Jan;83(1):62-7. doi: 10.1016/j.contraception.2010.05.014. Epub 2010 Jun 23.
- Panelli DM, Phillips CH, Brady PC. Incidence, diagnosis and management of tubal and nontubal ectopic pregnancies: a review. Fertil Res Pract. 2015 Oct 15;1:15. doi: 10.1186/s40738-015-0008-z. eCollection 2015.
- Diagnosis and Management of Ectopic Pregnancy: Green-top Guideline No. 21. BJOG. 2016 Dec;123(13):e15-e55. doi: 10.1111/1471-0528.14189. Epub 2016 Nov 3. No abstract available. Erratum In: BJOG. 2017 Dec;124(13):e314.
- Odejinmi F, Huff KO, Oliver R. Individualisation of intervention for tubal ectopic pregnancy: historical perspectives and the modern evidence based management of ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:69-75. doi: 10.1016/j.ejogrb.2016.10.037. Epub 2016 Oct 29.
- Albrecht ED, Aberdeen GW, Pepe GJ. The role of estrogen in the maintenance of primate pregnancy. Am J Obstet Gynecol. 2000 Feb;182(2):432-8. doi: 10.1016/s0002-9378(00)70235-3.
- National Collaborating Centre for Ws, Children's H. National Institute for Health and Clinical Excellence: Guidance. Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage. London: Rcog National Collaborating Centre for Women's and Children's Health.; 2012.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Pregnancy Complications
- Pregnancy, Ectopic
- Cardiac Complexes, Premature
- Pregnancy, Tubal
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
Other Study ID Numbers
- UW 20-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tubal Pregnancy
-
Shanghai First Maternity and Infant HospitalShanghai Pudong Hospital; Shanghai Seventh People's Hospital; Shanghai Zhoupu...Not yet recruitingTubal Pregnancy | Tubal-preserving Treatment of Tubal Ectopic Pregnancy | Pregnancy PreparationChina
-
Jagiellonian UniversityCompleted
-
Hopital Antoine BeclereUnknown
-
Mỹ Đức HospitalRecruiting
-
Sohag UniversityRecruitingWoman With Tubal Ectopic PregnancyEgypt
-
University of Alabama at BirminghamTerminatedTubal Ligation | Bilateral Tubal LigationUnited States
-
Woman's Health University Hospital, EgyptCompleted
-
EngenderHealthUnited States Agency for International Development (USAID); Tanzania Ministry... and other collaboratorsCompletedSterilization, TubalTanzania
-
Mayo ClinicCompletedTubal SterilizationUnited States
-
University of Sao Paulo General HospitalCompleted
Clinical Trials on Letrozole tablets
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Mylan Pharmaceuticals IncCompleted
-
Mylan Pharmaceuticals IncCompleted
-
EgymedicalpediaCompletedPCOS (Polycystic Ovary Syndrome) of Bilateral OvariesEgypt
-
Zagazig UniversityActive, not recruitingGestational Trophoblastic DiseaseEgypt
-
Tolmar Inc.RecruitingBreast CancerUnited States, Mexico, Brazil, Canada, Puerto Rico, Argentina
-
Tolmar Inc.Enrolling by invitationBreast CancerUnited States, Puerto Rico
-
Zagazig UniversityCompleted
-
Al-Mustansiriyah UniversityAl-Nahrain UniversityCompletedInfertility, Male | Male Reproductive ProblemIraq
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam